



CIN : L65910MH1992PLC067632

Date: 16<sup>th</sup> February, 2026

To,  
**BSE Limited**  
Department of Corporate Services  
P. J. Towers,  
Dalal Street, Fort,  
Mumbai – 400001.  
**Scrip Code: 511523**

**Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 — Press Release**

Dear Sir/ Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find enclosed herewith our Press Release on Un-Audited Financial Results for the Quarter and Nine months ended December 31, 2025.

We request you to kindly take the above on record.

Thanking you,

Yours truly,  
For **Veerhealth Care Limited**

Bhavin S. Shah  
Managing Director  
DIN: 03129574





**Veerhealth Care Limited Reports Robust 474.18% YoY growth at ₹ 0.40 Crore in PAT and 73.13% YoY growth at ₹ 6.96 in Total Income in Q3FY26**

**Mumbai – 16<sup>th</sup> February, 2026:** Veerhealth Care Limited (BSE: VEERHEALTH), Ayuveer, backed by Veerhealth Care's expertise in Ayurveda, specializes in crafting ayurvedic medicines and oral care products with natural ingredients. With a focus on quality and affordability, Ayuveer aims to offer an exceptional and safe daily care experience to its customers.

**Q3 FY26 Standalone Financial Highlights**

- Total Income of ₹ 6.96 Crore, YoY growth of 73.13%
- EBITDA of ₹ 0.94 Crore, YoY growth of 181.44%
- EBITDA Margin of 13.36% YoY growth of 490 BPS
- Net Profit of ₹ 0.40 Crore, YoY growth of 474.18%
- Net Profit Margin of 5.81%, YoY growth of 408 BPS

**Key Highlights**

- **After reduction of Tariffs by USA the company is expecting substantial increase in USA Export business.**
- **The India-EU Trade Deal 2026 is transforming the future of Modern Ayurveda exports from India, opening new growth opportunities in the global wellness market. With reduced tariffs, improved regulatory access, and rising European demand for natural healthcare, Indian Ayurvedic products are gaining strong momentum in the European Union.**  
**From Ayurvedic medicines and herbal supplements to organic skincare and wellness tourism, India's traditional healing system is becoming a major contributor to the global herbal products market.**
- Veerhealth Care has received USFDA clearance, enabling exports of Drug (OTC) products to the USA and unlocking access to other international markets, in line with its "Local to Global" vision. It is one of the leading small-cap companies in India in the Food & Drug (OTC) segment with a USFDA-approved plant. Despite its size, the Company is now in the league of larger players, eligible for larger export orders. Globally, very few small-cap companies have secured USFDA plant clearance, positioning Veerhealth Care in a distinctive category.
- In line with its "Local to Global" ambition, Veerhealth Care is actively working towards scaling its manufacturing and export operations for products under the medical device category in the U.S. market. The Company has successfully completed the formalities with the USFDA under this category, marking a strategic move to diversify and strengthen its international footprint in the healthcare segment.
- Received regulatory approval from Food and Drug Authority, Gujarat for manufacturing personal care products for a leading marketplace company.

- Discussions ongoing with a major Russian group for oral care exports; expected entry into Russian market soon.
- Completed onboarding of Ayuveer products on Myntra, expanding e-commerce presence. Now present across Amazon and Flipkart as well.
- Commenced production at new facility with in-house plastic molding for packaging and backward integration.

**Commenting on the financial performance, Mr. Bhavin Shah - Managing Director of Veerhealth Care Limited, said,** "I am delighted with the strides we have made in Q3 FY26, driven by our consistent focus on expanding our international footprint and strengthening our domestic presence. The growth in our Export Sales and the addition of new product categories have significantly bolstered our position in the global and local markets. **Going ahead we expect to maintain the high growth rates which we have delivered in this Quarter.**

Our ability to secure multiple high-value export orders, including those from top institutional suppliers, underscores the trust in our product quality and commitment to excellence. The expansion of our manufacturing footprint further reflects our proactive approach to meeting growing demand and enhancing our production capabilities. These achievements are a testament to our strategy and pave the way for sustained growth and value creation in the coming quarters."

**Globally, very few small-cap companies have secured USFDA approval, positioning Veerhealth Care in a distinctive category.**

**In F.Y. 2026-27 we are expecting Total Revenues of ₹ 45-50 crores with PAT of 7-10%.**

**Veerhealth Care is expecting to reach Revenue of ₹ 100 crores with PAT of 10% in next 24 months.**

#### **Disclaimer**

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. The Company will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

